Compare GRBK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRBK | TARS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 620 | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | GRBK | TARS |
|---|---|---|
| Price | $65.56 | $70.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $71.00 | ★ $89.00 |
| AVG Volume (30 Days) | 168.0K | ★ 409.6K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $0.07 | $55.67 |
| Revenue Next Year | $10.33 | $30.64 |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $50.57 | $38.51 |
| 52 Week High | $80.97 | $85.25 |
| Indicator | GRBK | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 54.02 |
| Support Level | $60.99 | $65.62 |
| Resistance Level | $65.80 | $78.34 |
| Average True Range (ATR) | 1.62 | 3.04 |
| MACD | 0.37 | 0.25 |
| Stochastic Oscillator | 93.29 | 81.80 |
Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment, which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgages and title.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.